Page last updated: 2024-12-11

s-trans,trans-farnesylthiosalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

farnesylthiosalicylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5469318
CHEMBL ID23293
CHEBI ID177460
MeSH IDM0246161

Synonyms (75)

Synonym
farnesylthiosalicyclic acid
bdbm50034278
2-((2e,6e)-3,7,11-trimethyl-dodeca-2,6,10-trienylsulfanyl)-benzoic acid
HY-14754
CHEBI:177460
2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulanylbenzoic acid
nsc-685986
kd-032
salirasib
farnesylthiosalicylic acid
ono-7056
EU-0100517
lopac-f-8175
NCGC00015448-01
LOPAC0_000517
s-trans,trans-farnesylthiosalicylic acid
nsc685986
2-(((2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid
salirasib [usan]
s-farnesylthiosalicylic acid
NCGC00093912-02
NCGC00093912-01
benzoic acid, 2-(((2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-
NCGC00015448-02
F 8175
CHEMBL23293 ,
162520-00-5
D08995
salirasib (inn/usan)
2-(3,7,11-trimethyldodeca-2,6,10-trienylsulfanyl)benzoic acid
2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid
CCG-204607
unii-mzh0om550m
mzh0om550m ,
salirasib [usan:inn]
NCGC00015448-03
CS-0681
farnesyl thiosalicylic acid
S7684
trans,trans farnesyl thiosalicylic acid
2-[[(2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic acid
farnesylthiosalicylate
gtpl6281
MLS006010835
smr004701762
salirasib [inn]
salirasib [who-dd]
WUILNKCFCLNXOK-CFBAGHHKSA-N
AKOS024458453
2-((2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid
EX-A1170
farnesylthiosalicylic acid, >98% (hplc), solid
mfcd00467723
2-{[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl}benzoic acid
AS-73028
salirasib, >=98% (hplc)
J-009946
sr-01000075885
SR-01000075885-1
DB12681
Q27088685
s-farnesylthiosalicylic acid;farnesyl thiosalicylic acid;fts
BCP27978
benzoic acid, 2-[[(2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]-
NCGC00015448-11
AMY39921
2-(((2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)benzoic acid
A882836
fts farnesylthiosalicylate
AC-35983
nsc755771
nsc-755771
salirasib; fts
DTXSID501025654
2-[[(2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienyl]thio]benzoic acid

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The abovementioned activity of VPA as a differentiation agent suggested that it might be worth investigating its possible therapeutic potential in synergistic combination with FTS."( Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Biran, A; Brownstein, M; Haklai, R; Kloog, Y, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" One of the ways to improve its therapeutic potential would be to enhance its bioavailability to cancer tissue by developing a method for targeted delivery."( Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.
Chordia, MD; Chung, LW; Guan, Y; Li, J; Liu, ZQ; Pan, D; Wang, JP; Xiao, L; Yue, W; Zhang, Y, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" After a single oral administration in Balb/c mice, the relative bioavailability of FTS-IR783 was increased by 90."( Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice.
Deng, JH; Guan, Y; Huang, QJ; Huang, ZY; Liao, GC; Liu, ZQ; Lu, LL; Pan, DF; Qi, XX; Wang, Y; Yang, ML; Yao, JJ; Zhang, FX; Zhang, YM; Zhuang, XR, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" We examined the dose-response effects of FTS on the growth of MCF-7 breast cancer cells in vitro and in vivo."( Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
Lynch, AR; McPherson, RA; Neal, LR; Santen, RJ; Yue, W, 2006
)
0.33
" Patients with stable disease or better repeated the dosing regimen."( An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.
Fujisaka, Y; Furuse, J; Iwasa, T; Kitamura, H; Kurata, T; Nagashima, F; Nakagawa, K; Naruge, D; Okano, N; Shimizu, T, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sesquiterpenoidAny terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (42)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency18.96620.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency18.96620.025120.237639.8107AID886; AID893
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency17.55950.125919.1169125.8920AID2353; AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID2323
endonuclease IVEscherichia coliPotency22.38720.707912.432431.6228AID1708
NFKB1 protein, partialHomo sapiens (human)Potency0.00320.02827.055915.8489AID895; AID928
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency25.11890.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926
pyruvate kinaseLeishmania mexicana mexicanaPotency31.62280.398113.744731.6228AID945; AID959
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency31.62280.540617.639296.1227AID2364; AID2528
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
DNA polymerase betaHomo sapiens (human)Potency31.62280.022421.010289.1251AID485314
DNA polymerase eta isoform 1Homo sapiens (human)Potency31.62280.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency25.11890.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency11.22020.004611.374133.4983AID463097
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency56.23410.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.04470.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency0.00400.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency20.20270.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)IC50 (µMol)25.50001.50002.05792.4000AID664675
Protein-S-isoprenylcysteine O-methyltransferase Rattus norvegicus (Norway rat)Ki2.80002.80002.80002.8000AID161439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)3.40790.00033.166210.0000AID1549771; AID1549788; AID482138
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
C-terminal protein methylationProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein targeting to membraneProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein modification processProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
S-adenosylhomocysteine metabolic processProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
S-adenosylmethioninamine metabolic processProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein C-terminal carboxyl O-methyltransferase activityProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activityProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein bindingProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endoplasmic reticulumProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
endoplasmic reticulum membraneProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
membraneProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
endoplasmic reticulumProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (90)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID664675Inhibition of ICMT in cell free system2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.
AID1062762Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 12 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 3.87%)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1062753Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 12 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 93.81%)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID601705Induction of apoptosis in human L02 cells at 8 uM after 48 hrs using annexin V/propidium iodide staining by flow cytometry2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1062745Inhibition of Ras in human SMMC7721 cells assessed as reduction in phosphorylated Akt level at 12 uM after 8 hrs by immunoblotting analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID601624Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1062764Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID410554Cytotoxicity against human U87 cells after 5 to 7 days2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
AID480850Cytotoxicity against human U251 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID67431The highest nontoxic concentration for human Ha-ras-transformed rat 1 (EJ) cells was determined by MTT staining method1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
AID1893930Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID1062768Cytotoxicity against human EJ cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1549788Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-3/acetoxymethyl ester dye based FLIPR analysis2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID601805Inhibition of Ras in human SMMC7721 cells xenografted in nude BALB/c mouse liver tumor homogenates assessed as reduction of phosphorylated Akt levels at 16 mg/kg by dendimetric scanning2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1143725Inhibition of PMPMEase (unknown origin) using RD-PNB as substrate incubated for 15 mins prior to substrate addition measured after 2 hrs by RP-HPLC analysis2014European journal of medicinal chemistry, Jun-23, Volume: 81Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
AID1143729Cytotoxicity against human BxPC3 cells at 20 uM after 24 to 72 hrs by fluorescence assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
AID1062767Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1549807Agonist activity at human TRPA1 Cys261Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 1 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1893929Inhibition of cell growth in rat Rat1 cells transfected with HRAS2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID601621Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID410553Cytotoxicity against human PANC1 cells after 5 to 7 days2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
AID1893932Toxicity in nude mouse xenografted with human PANC-1 cells assessed as reduction in body weight at 40 mg/kg, po administered daily for 10 days relative to control2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID480864Inhibition of Ras activation in human MDA-MB-231 cells assessed as reduction in phosphorylated Raf levels at 5 uM after 8 hrs by Western blot2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID1893937Antitumor activity against human SK-MES-1 HTB-58 cells xenografted in athymic nude mouse assessed as reduction in tumour volume at 10 mg/kg, ip administered once daily measured after 24 days2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID1062741Lipophilicity, log P of the compound in 10% PEG400 aqueous solution2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1515770Antimalarial activity against synchronized ring stage Plasmodium falciparum 3D7 transfected with nano-luciferase assessed as parasite growth inhibition at 200 uM after 72 hrs by Nano-Glo luciferase assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Repositioning Salirasib as a new antimalarial agent.
AID601804Inhibition of Ras in human SMMC7721 cells xenografted in nude BALB/c mouse liver tumor homogenates assessed as reduction of phosphorylated c-Raf levels at 16 mg/kg by dendimetric scanning2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID161438In vitro inhibition of Prenylated protein methyltransferase of rat brain cerebellar synaptosomes was assessed from the amount of [3H]-methyl esters formed in 15 min1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
AID410572AUC (0 to infinity) in Sprague-Dawley rat at 40 mg/kg, po2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
AID482138Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID601629Induction of apoptosis in human Hep3B cells at 8 uM after 48 hrs using annexin V/propidium iodide staining by flow cytometry2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID67432Effective concentration required for 50% inhibition of growth of human Ha-ras-transformed rat 1 (EJ)cells1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
AID1515767Antimalarial activity against synchronized ring stage Plasmodium falciparum 3D7 transfected with nano-luciferase assessed as parasite growth inhibition after 72 hrs by Nano-Glo luciferase assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Repositioning Salirasib as a new antimalarial agent.
AID1549771Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID601722Inhibition of Ras-mediated ERK phosphorylation at Thr202/Tyr204 in human SMMC7721 cells xenografted in nude BALB/c mouse liver tumor homogenates at 16 mg/kg, ip qd for 21 days by immunoblot analysis2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID161439Ability to inhibit prenylated protein methyltransferase (PPMTase) in cell free systems1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
AID664678Cytotoxicity against human PA-TU-8902 cells after 5 days by MTT assay2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.
AID1062770Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1143724Lipophilicity, log D of the compound2014European journal of medicinal chemistry, Jun-23, Volume: 81Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
AID1062769Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1893935Reduction in phosphor-ERK mutant level in tumor of human PANC-1 cells xenografted nude mouse at 40 mg/kg, po administered daily for 10 days by immunoblot analysis relative to control2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID1858656Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
AID664677Cytotoxicity against icmt-positive MEF cells after 5 days by MTT assay2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.
AID410568Elimination half life in Sprague-Dawley rat at 40 mg/kg, po2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
AID601626Induction of nitric oxide production in human L02 cells assessed as nitrite/nitrate levels at 100 uM after 30 to 300 mins by Griess assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1062766Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID601625Induction of nitric oxide production in human HepG2 cells assessed as nitrite/nitrate levels at 100 uM after 30 to 300 mins by Griess assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1062742Aqueous solubility of the compound in 10% PEG400 aqueous solution after 24 hrs by HPLC analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1062756Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 12 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.77%)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID480651Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID480650Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID1062759Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 12 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 1.55%)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID601721Inhibition of Ras-mediated Akt phosphorylation at S473 in human SMMC7721 cells xenografted in nude BALB/c mouse liver tumor homogenates at 16 mg/kg, ip qd for 21 days by immunoblot analysis2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID480851Cytotoxicity against human U87 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID1515769Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for synchronized ring stage Plasmodium falciparum 3D7 transfected with nano-luciferase2019MedChemComm, Sep-01, Volume: 10, Issue:9
Repositioning Salirasib as a new antimalarial agent.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID601622Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1062743Inhibition of Ras in human SMMC7721 cells assessed as reduction in phosphorylated ERK2 level at 12 uM after 8 hrs by immunoblotting analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID1515766Antimalarial activity against synchronized ring stage Plasmodium falciparum 3D7 assessed as parasite growth inhibition measured after 24 to 96 hrs2019MedChemComm, Sep-01, Volume: 10, Issue:9
Repositioning Salirasib as a new antimalarial agent.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1515765Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Repositioning Salirasib as a new antimalarial agent.
AID480852Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID1893933Reduction in KRAS mutant level in tumor of human PANC-1 cells xenografted nude mouse at 40 mg/kg, po administered daily for 10 days by immunoblot analysis relative to control2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID1893936Antitumor activity against human A549 cells xenografted in athymic nude mouse assessed as reduction in tumour volume at 10 mg/kg, ip administered once daily measured after 24 days relative to control2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID601714Inhibition of Ras in human SMMC7721 cells xenografted in nude BALB/c mouse liver tumor homogenates assessed as reduction of phosphorylated ERK levels at 16 mg/kg by dendimetric scanning2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1062765Cytotoxicity against human H460 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID480862Inhibition of Ras activation in human MDA-MB-231 cells assessed as reduction in phosphorylated Akt levels at 5 uM after 8 hrs by Western blot2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID410570Cmax in Sprague-Dawley rat at 40 mg/kg, po2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
AID1549814Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 1 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1893931Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth at 100 uM measured after 7 days relative to control2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID1143726Cytotoxicity against human MIAPaCa2 cells harboring K-Ras mutant oncogene after 48 hrs by fluorescence assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1893934Reduction in KRAS-GTP mutant level in tumor of human PANC-1 cells xenografted nude mouse at 40 mg/kg, po administered daily for 10 days by immunoblot analysis relative to control2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID601623Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID480863Inhibition of Ras activation in human MDA-MB-231 cells assessed as reduction in phosphorylated ERK levels at 5 uM after 8 hrs by Western blot2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
AID1062744Inhibition of Ras in human SMMC7721 cells assessed as reduction in phosphorylated ERK1 level at 12 uM after 8 hrs by immunoblotting analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
AID601720Inhibition of Ras-mediated c-Raf phosphorylation at S259 in human SMMC7721 cells xenografted in nude BALB/c mouse liver tumor homogenates at 16 mg/kg, ip qd for 21 days by immunoblot analysis2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
AID1893938Antitumor activity against human A549 cells xenografted in athymic nude mice assessed as inhibition of tumor growth at 50 mg/kg, po administered daily measured after 16 days relative to control2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID1143727Cytotoxicity against human BxPC3 cells after 48 hrs by fluorescence assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
AID664676Cytotoxicity against icmt-double mutant MEF cells after 5 days by MTT assay2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.
AID1143728Cytotoxicity against human MIAPaCa2 cells harboring K-Ras mutant oncogene at 20 uM after 24 to 72 hrs by fluorescence assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346556Human TRPA1 (Transient Receptor Potential channels)2008Molecular pharmacology, Apr, Volume: 73, Issue:4
Activation of TRPA1 by farnesyl thiosalicylic acid.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (172)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (7.56)18.2507
2000's60 (34.88)29.6817
2010's88 (51.16)24.3611
2020's11 (6.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (2.87%)5.53%
Reviews10 (5.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other159 (91.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]